Published in J Virol on June 01, 1991
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol (1993) 5.17
Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol (1994) 3.28
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother (1997) 2.98
Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J Virol (1993) 2.65
Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol (1995) 2.24
Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. J Virol (1997) 1.47
Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology (2007) 1.46
Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. J Virol (1996) 1.40
Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates. Proc Natl Acad Sci U S A (1992) 1.37
N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure. J Virol (1996) 1.15
Virus receptors: implications for pathogenesis and the design of antiviral agents. Clin Microbiol Rev (1995) 1.07
Macrophage-tropic HIV induces and exploits dendritic cell chemotaxis. J Exp Med (2000) 0.96
Viral multiplicity of attachment and its implications for human immunodeficiency virus therapies. J Virol (1994) 0.95
Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1). PLoS One (2011) 0.90
Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages. J Virol (1995) 0.89
Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives. Adv Biol (2014) 0.81
Molecular determinants of the ratio of inert to infectious virus particles. Prog Mol Biol Transl Sci (2014) 0.79
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 22.26
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1985) 21.57
Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science (1987) 13.52
Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science (1990) 10.13
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A (1988) 8.40
Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology (1987) 7.92
Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A (1988) 7.74
Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen. J Immunol (1985) 7.35
Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell (1988) 7.01
Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A (1988) 6.74
Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci U S A (1989) 6.58
High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A (1990) 6.49
A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature (1988) 6.39
HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science (1986) 6.33
Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol (1988) 5.96
Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature (1990) 5.33
Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol (1991) 5.09
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol (1987) 5.03
Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains. Nature (1990) 4.70
HIV infection is blocked in vitro by recombinant soluble CD4. Nature (1988) 4.58
Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science (1990) 4.43
Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J (1986) 4.32
Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science (1987) 4.31
A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature (1988) 4.15
Designing CD4 immunoadhesins for AIDS therapy. Nature (1989) 4.00
Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J Virol (1991) 3.71
Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res Hum Retroviruses (1987) 3.67
Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature (1988) 3.63
Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature (1989) 3.54
The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4. Nature (1988) 3.47
HIV requires multiple gp120 molecules for CD4-mediated infection. Nature (1990) 3.37
Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol (1990) 3.35
Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science (1988) 3.08
Neutralizing monoclonal antibodies to the AIDS virus. AIDS (1988) 3.06
Quantitative infectivity assay for HIV-1 and-2. Nature (1988) 3.01
Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. J Virol (1989) 3.00
Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Res Hum Retroviruses (1988) 2.99
Substitution of murine for human CD4 residues identifies amino acids critical for HIV-gp120 binding. Nature (1988) 2.53
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med (1990) 2.40
Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis. Proc Natl Acad Sci U S A (1988) 2.21
Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor. J Clin Invest (1985) 2.21
Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules. Nature (1989) 2.17
Morphometric analysis of recombinant soluble CD4-mediated release of the envelope glycoprotein gp120 from HIV-1. AIDS Res Hum Retroviruses (1990) 2.13
Biological properties of a CD4 immunoadhesin. Nature (1990) 2.05
Viral persistence. Cell (1989) 2.02
Loss of envelope antigens of HTLV-III/LAV, a factor in AIDS pathogenesis? Lancet (1985) 1.84
The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study. Ann Intern Med (1990) 1.82
Effect of recombinant soluble CD4 in rhesus monkeys infected with simian immunodeficiency virus of macaques. Nature (1989) 1.55
Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4. J Virol (1989) 1.38
Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity. Science (1988) 1.32
CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus in vitro at multiple stages of the viral life cycle. Proc Natl Acad Sci U S A (1989) 1.30
Quantifying the infectivity of human immunodeficiency virus. Proc Natl Acad Sci U S A (1989) 1.26
Differences in the interaction of HIV-1 and HIV-2 with CD4. J Acquir Immune Defic Syndr (1990) 1.24
Linear versus conformational variation of V3 neutralization domains of HIV-1 during experimental and natural infection. AIDS (1989) 1.04
Inhibition of HIV-1 replication and syncytium formation by synthetic CD4 peptides. Arch Virol (1989) 0.85
Analytic results for quantifying HIV infectivity. Bull Math Biol (1989) 0.78
Improving the accuracy of PSI-BLAST protein database searches with composition-based statistics and other refinements. Nucleic Acids Res (2001) 22.33
Cell movement is guided by the rigidity of the substrate. Biophys J (2000) 13.84
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (1994) 13.54
AAA+: A class of chaperone-like ATPases associated with the assembly, operation, and disassembly of protein complexes. Genome Res (1999) 11.30
Nascent focal adhesions are responsible for the generation of strong propulsive forces in migrating fibroblasts. J Cell Biol (2001) 6.32
Cell adhesion. Competition between nonspecific repulsion and specific bonding. Biophys J (1984) 5.72
Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology (1992) 5.64
Prediction of immunodominant helper T cell antigenic sites from the primary sequence. J Immunol (1987) 4.95
Hydrophobicity scales and computational techniques for detecting amphipathic structures in proteins. J Mol Biol (1987) 4.07
Traction force microscopy of migrating normal and H-ras transformed 3T3 fibroblasts. Biophys J (2001) 4.01
Substrate flexibility regulates growth and apoptosis of normal but not transformed cells. Am J Physiol Cell Physiol (2000) 3.97
Traction forces in locomoting cells. Cell Motil Cytoskeleton (1995) 3.58
Focal adhesion kinase is involved in mechanosensing during fibroblast migration. Proc Natl Acad Sci U S A (2001) 3.41
HIV requires multiple gp120 molecules for CD4-mediated infection. Nature (1990) 3.37
Lineage-specific gene expansions in bacterial and archaeal genomes. Genome Res (2001) 3.10
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother (1997) 2.98
Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1992) 2.98
Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J Virol (1990) 2.65
Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual. J Immunol (1990) 2.57
Extending the range of rate constants available from BIACORE: interpreting mass transport-influenced binding data. Biophys J (1998) 2.49
Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses. J Virol (1987) 2.28
The role of the V3 loop of gp120 in HIV infection. AIDS (1991) 2.23
Separation of propulsive and adhesive traction stresses in locomoting keratocytes. J Cell Biol (1999) 2.16
The efficient computation of position-specific match scores with the fast fourier transform. J Comput Biol (2002) 2.12
Protein antigenic structures recognized by T cells: potential applications to vaccine design. Immunol Rev (1987) 1.95
Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J Virol (1992) 1.94
In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci U S A (1994) 1.93
Distinct roles of frontal and rear cell-substrate adhesions in fibroblast migration. Mol Biol Cell (2001) 1.93
Immunohistochemical localization of human and simian immunodeficiency viral antigens in fixed tissue sections. Am J Pathol (1987) 1.92
Cell motion, contractile networks, and the physics of interpenetrating reactive flow. Biophys J (1986) 1.88
Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol (1997) 1.77
Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses (1995) 1.72
Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J Virol (1993) 1.70
Conserved fragments of transposable elements in intergenic regions: evidence for widespread recruitment of MIR- and L2-derived sequences within the mouse and human genomes. Genet Res (2003) 1.63
Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120. J Virol (1989) 1.61
Motion of particles adhering to the leading lamella of crawling cells. J Cell Biol (1981) 1.60
Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles. Virology (1998) 1.57
Approximating the effects of diffusion on reversible reactions at the cell surface: ligand-receptor kinetics. Biophys J (1995) 1.53
Theory of equilibrium binding of symmetric bivalent haptens to cell surface antibody: application to histamine release from basophils. J Immunol (1978) 1.51
Candidate regulatory sequence elements for cell cycle-dependent transcription in Saccharomyces cerevisiae. Genome Res (1999) 1.49
Design and use of substrata to measure traction forces exerted by cultured cells. Methods Enzymol (1998) 1.47
Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. Proc Natl Acad Sci U S A (1987) 1.46
Genomic diversity and antigenic variation of HIV-1: links between pathogenesis, epidemiology and vaccine development. FASEB J (1991) 1.46
On the mechanics of the first cleavage division of the sea urchin egg. Exp Cell Res (1997) 1.41
Strong conformational propensities enhance T cell antigenicity. J Immunol (1987) 1.39
Cytoplasm dynamics and cell motion: two-phase flow models. Math Biosci (1999) 1.38
Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses (1990) 1.34
Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity. Science (1988) 1.32
MAP 30: a new inhibitor of HIV-1 infection and replication. FEBS Lett (1990) 1.30
Quantifying the infectivity of human immunodeficiency virus. Proc Natl Acad Sci U S A (1989) 1.26
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol (1995) 1.25
Aspiration of human neutrophils: effects of shear thinning and cortical dissipation. Biophys J (2001) 1.25
Kinetics of cell detachment: peeling of discrete receptor clusters. Biophys J (1994) 1.23
Hydrodynamics of micropipette aspiration. Biophys J (1999) 1.22
T cell multideterminant regions in the human immunodeficiency virus envelope: toward overcoming the problem of major histocompatibility complex restriction. Int Immunol (1989) 1.17
Absence of cytotoxic antibody to human immunodeficiency virus-infected cells in humans and its induction in animals after infection or immunization with purified envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1987) 1.14
Qualitative characteristics of histamine release from human basophils by covalently cross-linked IgE. J Immunol (1981) 1.13
Preliminary in vitro growth cycle and transmission studies of HIV-1 in an autologous primary cell assay of blood-derived macrophages and peripheral blood mononuclear cells. Virology (1996) 1.12
Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. J Clin Invest (1994) 1.10
Loss of infectivity by progeny virus from alpha interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gp120. J Virol (1992) 1.09
Modeling the reversible kinetics of neutrophil aggregation under hydrodynamic shear. Biophys J (1997) 1.06
Simultaneous isolation of simian foamy virus and HTLV-III/LAV from chimpanzee lymphocytes following HTLV-III or LAV inoculation. Arch Virol (1987) 1.05
Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization. AIDS Res Hum Retroviruses (1996) 1.05
Analysis of the cross-reactive anti-gp120 antibody population in human immunodeficiency virus-infected asymptomatic individuals. J Virol (1993) 1.05
Linear versus conformational variation of V3 neutralization domains of HIV-1 during experimental and natural infection. AIDS (1989) 1.04
Antigen-specific desensitization of human basophils. J Immunol (1979) 1.03
Reversible sodium pump defect and swelling in the diabetic rat erythrocyte: effects on filterability and implications for microangiopathy. Proc Natl Acad Sci U S A (1989) 1.02
Motion of polymorphonuclear leukocytes: theory of receptor redistribution and the frictional force on a moving cell. Cell Motil (1981) 1.02
Deceptive imprinting in the immune response against HIV-1. Immunol Today (1994) 1.00
Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1IIIB GP120 peptide RP135. Biochemistry (1997) 0.97
Numerical studies of unreactive contractile networks. Biophys J (1986) 0.95
The facilitated diffusion of oxygen by hemoglobin and myoglobin. Biophys J (1977) 0.94
Interaction between anions and the reduced folate/methotrexate transport system in L1210 cell plasma membrane vesicles: directional symmetry and anion specificity for differential mobility of loaded and unloaded carrier. J Membr Biol (1984) 0.93
Heat-labile, complement-like factor(s) of animal sera prevent(s) HIV-1 infectivity in vitro. J Acquir Immune Defic Syndr (1990) 0.91
Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120). Vaccine (1989) 0.90
Analysis of B cell repertoire specific to the neutralizing epitopes of glycoprotein 120 in HIV-infected individuals. AIDS Res Hum Retroviruses (1994) 0.90
Histamine release due to bivalent penicilloyl haptens: control by the basophil plasma membrane. J Immunol (1978) 0.90
Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages. J Virol (1995) 0.89
The mechanics of motility in dissociated cytoplasm. Biophys J (1986) 0.89
Histamine release due to bivalent penicilloyl haptens the relation of activation and desensitization of basophils to dynamic aspects of ligand binding to cell surface antibody. J Immunol (1979) 0.89
Degranulation of human basophils: quantitative analysis of histamine release and desensitization, due to a bivalent penicilloyl hapten. J Immunol (1979) 0.88
A model of cell activation and desensitization by surface immunoglobin: the case of histamine release from human basophils. Cell (1980) 0.88
Effects of prednisolone on the development of immune responses to canine distemper virus in beagle pups. Am J Vet Res (1979) 0.88
Thermodynamics of cell adhesion. II. Freely mobile repellers. Biophys J (1986) 0.88
Test of a theory relating to the cross-linking of IgE antibody on the surface of human basophils. J Immunol (1985) 0.88
Lipoprotein-associated oncornavirus-inactivating factor in the genus Mus: effects on murine leukemia viruses of laboratory and exotic mice. Cancer Res (1987) 0.87
Decrease in cytokine production by HIV-infected macrophages in response to LPS-mediated activation. Lymphokine Cytokine Res (1991) 0.87
A thermodynamic model of binding of flexible bivalent haptens to antibody. Immunochemistry (1978) 0.86